6991-06-6Relevant articles and documents
COMBINATION DRUG
-
Page/Page column 77, (2010/02/12)
The present invention provides pharmaceutical agents comprising a dipeptidyl peptidase IV (DPPIV) inhibitor and a biguanide agent in combination, which enhance the effects of active circulating glucagon-like peptide-1 (GLP-1) and/or active circulating glucagon-like peptide-2 (GLP-2).
A one-pot preparation of 1-benzyl-2'-deoxyinosine from ionized 2'-deoxyinosine
Moon,Kim
, p. 1135 - 1143 (2007/10/03)
A simple and one step synthetic method for the formation of 1-benzyl-2'-deoxyinosine was developed by direct benzylation of ionized 2'-deoxyinosine. Treatment of 2'-deoxyinosine, in the presence of NaOH, with benzyl bromide in 2,2,2-trifluoroethanol (TFE) or N,N-dimethylaetamide (DMA) gave 1-benzyl-2'-deoxyinosine in 35% and 80% yields, respectively.
Purines. LX. Dimroth rearrangement and concomitant hydrolytic deamination of 7-alkyl-1-methyladenines
Fujii,Saito,Ii,Suzuki
, p. 382 - 384 (2007/10/02)
The Dimroth rearrangement of 7-alkyl-1-methyladenines (8) to produce 7- alkyl-N6-methyladenines (9) (63-72% yield) has been found to be accompanied with unusual hydrolytic deaminations to give 7-alkyl-1-methyl-hypoxanthines (10) (1-3.5%) and/or 7-alkylhypoxanthines (11) (12-22%), when effected in boiling H2O for 4-70 h. Probable pathways leading to these by-products are proposed.